Skip to main content

Indaptus Therapeutics, Inc.

INDP
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001857044

No open-market purchases or sales by Indaptus Therapeutics, Inc. insiders were filed in the last 90 days; 9 institutions reported holding it in 13F filings for Q2 2026, worth $1.15M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Indaptus Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Indaptus Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Indaptus Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Lazar David E.Director–Mar 24, 20261
Jabbour Jerome DDirector–Feb 27, 20261
Meckler Jeffrey ACo-Chief Executive Officer229,929Feb 13, 20262
Natan DavidDirector–Jan 22, 20261
Ben-Tzvi AvrahamDirector25,100Jan 22, 20261
Linscott Walt AddisonChief Operating Officer54,426Dec 29, 20251
Sassi NirChief Financial Officer26,758Dec 29, 20251
Newman Michael JamesCSO and Director101,074Dec 29, 20251
Hayes William BDirector–Jun 11, 20250
Martell RobertDirector–Jun 11, 20250
Maddaluna Anthony JDirector–Jun 11, 20250
Pomerantz RogerDirector–Jun 11, 20250
Karah HilaDirector–Jun 11, 20250
Gilbert Mark JohnDirector–Jun 11, 20250
Waltzman Roger J.Chief Medical Officer–Oct 10, 20240
Anderson Glen R.10% Owner1,190,400IndirectAug 16, 20230
Litchev Boyan VesselinovChief Medical Officer1,150Dec 19, 20220
O'Callaghan BrianDirector–Oct 3, 20220
Lee HoonmoDirector–Aug 6, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Mar 24, 2026 (view filing)Mar 231 dayLazar David E.DirectorSSale−108.9M–––0 afterDerivative2 lots
Aug 16, 2023 (view filing)Aug 10-146 daysLateAnderson Glen R.10% OwnerPPurchase+103.4K$2.09+$216.4K+9.5%1.19M after3 lots
Dec 19, 2022 (view filing)Jan 31-Dec 1322 daysLateLitchev Boyan VesselinovChief Medical OfficerPPurchase+1.15K$2.19+$2.52KNew position1.15K after4 lots
Nov 22, 2022 (view filing)Nov 18-214 daysMeckler Jeffrey ACEO and DirectorPPurchase+10.0K$1.89+$18.9K+15.3%75.4K after2 lots
Sep 12, 2022 (view filing)Sep 84 daysMeckler Jeffrey ACEO and DirectorPPurchase+10.3K$2.80+$28.9K+18.7%65.4K after
Sep 9, 2022 (view filing)Sep 72 daysLinscott Walt AddisonChief Business OfficerPPurchase+150$2.62+$393New position150 after
Sep 8, 2022 (view filing)Sep 6-72 daysMeckler Jeffrey ACEO and DirectorPPurchase+9.69K$2.56+$24.8K+21.4%55.1K after2 lots
Jun 7, 2022 (view filing)Jun 61 dayMeckler Jeffrey ACEO and DirectorPPurchase+19.7K$2.63+$51.9K+76.9%45.4K after
Feb 2, 2022 (view filing)Jan 31-Feb 12 daysNewman Michael JamesCSO and DirectorSSale−20.0K$5.00−$100.0K−1.4%1.37M after2 lots
Nov 19, 2021 (view filing)Nov 181 dayMeckler Jeffrey ACEO and DirectorPPurchase+11.2K$5.82+$65.1K+77.4%25.6K after
Sep 16, 2021 (view filing)Sep 142 daysMeckler Jeffrey ACEO and DirectorPPurchase+12.0K$7.00+$84.0K+487.8%14.5K after